A Phase II study of preoperative chemotherapy with docetaxel, oxaliplatin and S-1 in gastric cancer with extensive lymph node metastasis (JCOG1704).
Yuya SatoYukinori KurokawaYuichiro DokiJunki MizusawaKiyo TanakaHiroshi KatayamaNarikazu BokuTakaki YoshikawaMasanori Terashimanull nullPublished in: Future oncology (London, England) (2020)
Background: Although surgical resection is necessary to cure the locally advanced gastric cancer, it is sometimes difficult for extensive nodal metastasis such as para-aortic nodal disease or bulky nodal metastasis around the major gastric branched arteries. We had conducted several Phase II studies and clarified preoperative chemotherapy with doublet regimen followed by surgery markedly improved the survival for this disease. Recently, preoperative chemotherapy with docetaxel, oxaliplatin and S-1 (DOS) showed promising efficacy and acceptable feasibility for resectable advanced gastric cancer. Aim: To describe the design and rationale for the multi-institutional, single-arm, Phase II trial of systemic chemotherapy with DOS followed by surgery in advanced gastric cancer with extensive lymph node metastasis (JCOG1704). If efficacy and safety of DOS can be shown, we will conduct a Phase III trial comparing preoperative DOS and current standard cisplatin and S-1. Trial registration: jRCTs031180028.
Keyphrases
- locally advanced
- neoadjuvant chemotherapy
- phase iii
- lymph node metastasis
- phase ii study
- phase ii
- squamous cell carcinoma
- open label
- clinical trial
- rectal cancer
- placebo controlled
- radiation therapy
- patients undergoing
- papillary thyroid
- double blind
- coronary artery bypass
- minimally invasive
- study protocol
- randomized controlled trial
- aortic valve
- left ventricular
- acute coronary syndrome
- pulmonary artery